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Abstract
Background: Burn patients with AKI have a higher mortality, rapid diagnosis and early treatment of AKI are
necessary. Recent studies have demonstrated that urinary KIM-1 and IL-18 are potential biomarkers of early-stage
AKI, however, changes in urinary KIM-1 and IL-18 levels are unclear in patients with burns. The aim of our study was
to determine whether combined KIM-1 and IL-18 are more sensitive than traditional markers in detecting kidney
injury in patients with burns.
Methods: Ninety-five burn patients hospitalized at the Burns and Plastic Surgery Center of our hospital from April 2013
to September 2013 were enrolled into this prospective study and divided into mild- (n = 37), moderate- (n = 30) and
severe-burn groups (n = 28) by burn injury surface area. In the moderate- and severe-burn groups, patients were
subcategorized to either the acute kidney injury (AKI) group, in which serum creatinine (Scr) increased to ≥26.5 μmol/L
within 48 h, or the non-AKI group. Fifteen healthy subjects were selected as a control group. Blood specimens were
collected to determine blood urea nitrogen (BUN), Scr, and other biochemical indicators. Urine samples collected at
admission and 48 h after admission were analyzed for KIM-1 and IL-18. Correlations among urinary KIM-1 and IL-18,
burn degree, and clinical biochemical indicators were investigated.
Results: AKI occurred in 11.2 % of burn patients (none in the mild-burn group). AKI developed 48 h after admission in
10.0 % of the moderate- and 28.6 % of the severe-burn groups. Urinary KIM-1 concentration in the moderate- and
severe-burngroupswassignificantlyhigherthanthat inthecontrolgroup;urinary IL-18concentrationsdidnotdiffer
significantlyamongtheburnandcontrolgroups.TheAKIgrouphadsignificantlyhigherconcentrationsofurinaryKIM-1
andIL-18thanthenon-AKIgroup,bothatadmission(p = 0.001andp < 0.001, respectively)and48hlater (p = 0.001and
p < 0.001, respectively).BothurinaryKIM-1andIL-18increasedbeforeScr.Receiveroperating-curve(ROC)analysis
demonstratedthatKIM-1combinedwithIL-18predictedAKIwith72.7%sensitivityand92.8%specificity.Theareaunder
theROCcurvewas0.904.
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Background
Acute kidney injury (AKI), a common and serious compli-
cation of large-area burns, is a critical condition clinically
characterized by oliguria and elevated serum creatinine
(Scr) [1]. The incidence of AKI is 45.5 %; severe AKI
occurs in 0.5 to 30 % of burn patients and is associated
with the size and severity of the burn [1, 2]. Patients with
AKI tend to have higher mortality than those without
AKI; in particular, the mortality associated with burns and
severe AKI is greater than 80 % [2–4]. Therefore, early
diagnosis of AKI is important to undertaking effective
treatment [5].
According to the Kidney Disease Improving Global
Outcomes (KDIGO) 2012 AKI guidelines, AKI is de-
fined as an increase in Scr to ≥26.5 μmol/L within 48 h,
or to ≥1.5 times the baseline value within 7 days. How-
ever, the guidelines use urine output and Scr values as
staging criteria. Moreover, because Scr is affected by
many factors and has low sensitivity and specificity for
an association with AKI, it is particularly important to
determine other biomarkers of early kidney injury that
are sensitive, specific, and reliable. Numerous studies
conducted in recent years have indicated that factors
such as kidney injury molecule-1 (KIM-1), interleukin-
18 (IL-18), N-acetyl-β-glucosidase (NAG) and neutro-
phil gelatinase-associated lipocalin (NGAL) increase in
the early stages of AKI and can therefore be used as
markers for early AKI diagnosis [6–9].
Because burn patients with AKI have a higher mortal-
ity, rapid diagnosis and early treatment of AKI are
necessary. Few studies have demonstrated the ability of
NGAL to reflect the severity of renal injury or to be used
as an indicator of inflammation in burn patients [10]
even though plasma and urinary NGAL levels within
48 h after admission have been independently associated
with AKI development and mortality [11].
Recent studies have demonstrated that urinary KIM-1
and IL-18 are potential biomarkers of early-stage AKI
caused by contrast-induced nephrotoxicity, cardiac sur-
gery, and preeclampsia [12–14], and can reveal AKI
much earlier than canScr. However, changes in urinary
KIM-1 and IL-18 levels are unclear in patients with
burns. The aim of our study was therefore to determine
whether combined KIM-1 and IL-18 are more sensitive




One hundred thirty-one burn patients hospitalized at the
Burns and Plastic Surgery Center of our hospital from April
2013 to September 2013 were selected. Exclusion criteria
were: 1) age <15 years or >65 years; 2) receiving nephro-
toxic drugs prior to admission; 3) previous history of heart
failure, coronary heart disease, chronic liver disease, or end-
stage renal disease; 4) the time of burn more than 12 h
before admission; and 5) chemical burn. Ultimately, 95
burn patients were enrolled in this study. Patients were
divided into mild- (n = 37), moderate- (n = 30), and
severe-burn (n = 28) groups based on total body surface
area (TBSA), burn depth, and complications. Those
with second-degree TBSA <10 % were assigned to the
mild-burn group, and those with second-degree TBSA
of approximately 11–30 % or third-degree TBSA <10 %
were assigned to the moderate-burn group. Those with
second-degree TBSA exceeding 31 % with third-degree
TBSA >10 %, or whose second- or third-degree TBSA
had not yet reached the previously defined percentages
but who had shock or other complications, including
respiratory burns or severe combined injuries, were
assigned to the severe-burn group [2]. Additionally, 15
healthy volunteers from the medical center of our
hospital over the same period were selected as the con-
trol group.
Clinical data, including age, sex, third-degree-burn
area, presence of inhalation injury, presence of rhabdo-
myolysis, and APACHE II score on admission and 48 h
after admission, were collected from all patients. A
patient was diagnosed with AKI if Scr had increased to
meet the AKI criteria according to KDIGO guidelines by
48 h after admission.
This study was approved by the Ethical Review Board of
the HuaiHai Hospital of Xuzhou Medicine College,China.
Each participant provided written informed consent for
participation in the study; however, any participant who
could not personally complete the informed-consent form
did so with the assistance of his or her parent or a relative.
Collection, preservation, and testing of urine specimens
Clean-catch midstream urine specimens were collected
from patients in each group at the time of admission
and were collected again 48 h after admission. Patients
with compromised mental status were given an indwell-
ing catheter to obtain clean urine. After centrifugation
for 5 min at 3,000 rpm, the supernatant was transferred
into Eppendorf tubes and stored in a freezer at −80 °C.
Urine specimens for the control group were also
collected and stored at −80 °C.
Urinary KIM-1 and IL-18 levels were measured by
enzyme-linked immunosorbent assay (ELISA) (Human
TIM-1/KIM-1/HAVCR Quantikine ELISA Kit, R&D
Systems, Minneapolis, MNUSA; Human IL-18 Plat-
inum ELISA, eBioscience, Inc, San Diego, CA, USA).
Optical density was read at 450 nm (Model 450 Mi-
croplate Reader; Bio-Rad Laboratories, Inc., Hercules,
CA, USA), and the test-sample concentrations were
calculated using a standard curve.
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Blood-specimen testing
Blood samples were also collected at, and 48 h after, the
time of admission. After routine blood examination, a
model 7000 Automatic Biochemical Analyzer (Hitachi
High Technologies America, Inc., Schaumberg, IL, USA)
was used to determine Scr as well as serum alanine ami-
notransferase (ALT), aspartate aminotransferase (AST),
albumin (Alb), blood urea nitrogen (BUN), and creatine
kinase (CK).
Statistical analysis
PASW Statistics for Windows, Version 18.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analyses.
Results are expressed as mean ± standard deviation, me-
dian and interquartile range, or number and percentage.
Student’s t-test was applied to parametric data and the
Mann–Whitney U- test to nonparametric data. Inter-
group comparisons were performed using analysis of
variance. The chi-square test was applied to data
expressed as a rate. Pearson correlation analysis was also
used. The diagnostic abilities of urinary KIM-1 and IL-
18 levels to predict AKI were assessed by calculating the
areas under the receiver operating characteristic (ROC)
curves (AUC) and the cutoff value was defined by You-
den’s index.
In addition, Stata 13.0 statistical software (StataCorp
LP, College Station, TX, USA) was used for the Net Re-
classification Improvement (NRI) and Integrated Dis-
crimination Improvement (IDI) analyses for KIM-1 and
IL-18.
Differences with p values <0.05 were considered statis-
tically significant.
Results
Table 1 presents clinical data, including TBSA calcula-
tion, laboratory results, and burn-group assignments
performed at admission, for the 95 study patients.
Laboratory parameters and urinary KIM-1 and IL-18 levels
There were no significant differences in Scr or BUN
levels among the mild-, moderate-, and severe-burn and
control groups at admission (Table 1).
Urinary KIM-1 levels increased with burn severity, and
significant differences were observed among groups.
Urinary IL-18 levels did not differ significantly among
groups (Table 1).
Development of AKI in burn patients
The incidence of AKI in burn patients within 48 h after
admission was 11 of 95 patients (11.2 %). No patients in
the mild-burn group, three of the 30 patients in the
moderate-burn group (10 %), and eight of 28 patients in
the severe-burn group (28.6 %) developed AKI within
48 h after admission. The incidence of AKI in the
severe-burn group was significantly higher than that in
the moderate-burn group (Fig. 1). These 11 of 58 pa-
tients with moderate and severe burns were sub-
categorized to the AKI group (seven males, four females;
age, 33.4 ± 11.3 years). The KDIGO Guidelines on AKI
were used to classify five of the 11 as stage 2, five as
stage 3, and one as stage 1 AKI. The other patients in
the moderate- and severe-burn groups were sub-
categorized to the non-AKI group.
Comparisons between AKI and non-AKI groups
We observed significant differences in TBSA, third-
degree burn area (TDBA), proportion of patients with
inhalation injury, and incidence of rhabdomyolysis be-
tween the AKI and non-AKI groups at the time of ad-
mission (Table 2).
APACHE II score was significantly higher in the AKI
group than in the non-AKI group, both at the time of ad-
mission and 48 h after admission (Table 2), and was signifi-
cantly higher 48 h after admission than at the time of
admission in the AKI group. In addition, five patients
underwent mechanical-ventilation therapy and five were
treated with continuous renal replacement therapy (CRRT)
Table 1 Patient data for the control group and burn groups
Control (n = 15) Mild burn (n = 37) Moderate burn (n = 30) Severe burn (n = 28) p value
M/F 11/4 29/8 23/7 23/5 0.481
Age (y) 38.5 ± 10.2 31.5 ± 15.5 35.7 ± 18.4 40.6 ± 14.8 0.121
TBSA (%) / 7.01 ± 1.61 24.9 ± 3.48 44.4 ± 13.8 /
BUN (mmol/L) 4.14 ± 0.87 4.91 ± 1.53 4.79 ± 1.71 4.88 ± 0.88 0.161
Scr (μmol/L) 59.0 ± 8.73 54.6 ± 20.8 60.9 ± 20.9 60.9 ± 18.4 0.476
Urinary KIM-1 (ng/mL) 2.12 ± 0.80 2.65 ± 0.73 4.06 ± 1.38ab 5.06 ± 1.51abc 0.000
Urinary IL-18 (pg/mL) 6.04 ± 1.41 6.27 ± 2.84 6.93 ± 3.11 6.68 ± 2.66 0.671
Data expressed as mean ± standard deviation unless otherwise indicated. Alb, albumin; BUN, blood urea nitrogen; F, female; IL-18, interleukin-18; KIM-1, kidney
injury molecule-1; M, male; Scr, serum creatinine; TBSA, total burn surface area
avs. control group; bvs. mild-burn group; cvs. moderate-burn group
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during the 48 h after admission. In the AKI group, four
patients did not survive more than 4 weeks after admission.
Mortality in the AKI group was 36.4 % (Table 2).
Changes in urinary KIM-1 and IL-18 levels of the AKI
non-AKI groups between admission and 48 h after
admission
Scr and serum BUN levels in the AKI group were signifi-
cantly higher than those of the non-AKI group, both at
the time of admission and 48 h after admission (Table 2),
and were significantly higher 48 h after admission than
at the time of admission in the AKI group (Fig. 2a, b).
However, in the non-AKI group, only BUN was signifi-
cantly higher at 48 h than at admission (Fig. 2a).
Urinary KIM-1 levels were significantly higher in the
AKI group than in the non-AKI group both at the time
of onset (p = 0.001) and 48 h after admission (p < 0.001)
(Table 2). Levels of urinary KIM-1 and IL-18 did not dif-
fer significantly between admission and 48 h after admis-
sion in either group (Fig. 2c, d).
Relationship between urinary KIM-1 and IL-18 and Scr,
serum BUN, and other clinical parameters
Correlation analysis between the urinary KIM-1 and IL-18
levels and the clinical indicators of all 95 burn patients was
performed (Fig. 3). This demonstrated that urinary KIM-1
at the time of admission was positively correlated with Scr
(r = 0.358, p < 0.001) but not with BUN (r = 0.146, p =
0.157). Urinary IL-18 at admission was positively correlated
with both serum BUN (r = 0.344, p <0.001) and Scr (r =
0.489, p <0.001).
We also analyzed the relationships between urinary
KIM-1 and IL-18 and the age, TBSA, TDBA, presence of
rhabdomyolysis, and APACHE II scores of burn patients.
We observed significant positive correlations between
urinary KIM-1 and TBSA (r = 0.661, p < 0.001), TDBA (r
= 0.600, p <0.001), rhabdomyolysis (r = 0.466, p <0.001),
and APACHE II score (r = 0.534, p <0.001). However, only
urinary IL-18 and TDBA (r = 0.307, p = 0.002) were seen
to be significantly positively correlated. There was no sig-
nificant correlation between age and either KIM-1 (r =
0.079, p = 0.449) or IL-18 (r = 0.095, p = 0.361).
The power of urinary KIM-1 and IL-18 to predict AKI on
admission
To predict AKI on admission, ROC curves were drawn by
plotting sensitivity against 1 − specificity of urinary KIM-1
and IL-18, and the area under curve (AUC) was calculated
(Fig. 5). ROC/AUC analysis demonstrated a sensitivity of
72.7 % and a specificity of 86.9 %, (AUC= 0.846; 95 % con-
fidence interval [CI], 0.712–0.980) for a cutoff value of
5.33 ng/mL urinary KIM-1 (Fig. 4). The ROC curve showed
Fig. 1 Flowchart of patient selection. AKI, acute kidney injury; CRRT, Continuous renal replacement therapy
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the optimal cutoff for urinary IL-18 to be 6.39 pg/mL
(AUC= 0.819; 95 % CI 0.714–0.923) with a sensitivity of
100 % and a specificity of 56 % in predicting AKI (Fig. 4).
When we combined urinary KIM-1 and IL-18 using the
probability function in binary logistic regression, we
found that the ROC curve predicting the probability of
KIM-1 combined with IL-18 showed a sensitivity of
72.7 % and a specificity of 92.8 % (AUC = 0.904, 95 %
CI 0.822–0.987) (Fig. 5).
To estimate the predictive power of each biomarker, we
performed NRI and IDI analyses for early AKI and deter-
mined the NRI for urinary KIM-1 to be 0.9307 (standard
error [SE] = 0.3206, z = 2.9027, p = 0.0037), and for urinary
IL-18 to be 0.9069 (SE = 0.3206, z = 2.8284, p = 0.0047).
The IDI for urinary KIM-1 was 0.3068 (SE = 0.0953, z =
3.2180 and p = 0.0013); for urinary IL-18 the IDI was
0.1866 (SE = 0.0715, z = 2.6083, p = 0.0091).
Discussion
AKI is characterized as a rapid loss of kidney function
that clinically manifests as an abrupt and sustained rise
in urea and creatinine. Our prospective study found
that the urinary KIM-1 and IL-18 levels may be better
diagnostic biomarkers than Scr for early-stage AKI in
burn patients.
AKI is a common and serious complication following
severe burn injury and is associated with increased mor-
bidity, mortality, and hospitalization costs. An extensive
literature review that included approximately 35,000
burn patients found that AKI had a prevalence of 14.5 %
and an associated mortality rate of 77.3 % [15]; others
have reported that mortality rates among burn patients
who develop AKI range from 73 to 100 % [16, 17]. In
our study, we found the incidence of AKI, as defined by
KDIGO guidelines, among patients in the moderate- and
severe-burn groups to be 10.0 and 28.6 %, respectively,
and the mortality rate of burn patients with AKI to be
36.4 %. The high likelihood of developing AKI after burn
injury greatly increases mortality among burn patients,
particularly those with severe burns complicated by AKI.
Therefore, early identification of patients at risk for AKI
is important.
Although Scr is used routinely in clinical practice, it
may be a suboptimal marker of acute renal injury. In-
creased Scr is related more to loss of filtration function
than to acute tubular injury [18]. Because a detectable
Table 2 Clinical features and laboratory results of non-AKI and AKI groups
Non-AKI group (n = 47) AKI group (n = 11) p value
At the time of admission
Age (y) 39.1 ± 17.7 33.4 ± 11.3 0.309
gender (M/F) 39/8 7/4 0.154
TBSA (%) 32.0 ± 10.1 44.2 ± 22.4a 0.008
Third-degree burn area (%) 5(0,14) 27(9,48) 0.000
Inhalation injury,n (%) 6(12.8) 7(63.6) 0.000
Rhabdomyolysis,n (%) 5(10.6) 6(54.5) 0.001
BUN (mmol/L) 4.52 ± 1.14 7.02 ± 1.53 0.000
Scr (μmol/L) 55.2 ± 14.1 85.3 ± 21.6 0.000
Urinary KIM-1 (ng/mL) 4.23 ± 1.25 5.84 ± 1.89 0.001
Urinary IL-18 (pg/mL) 6.15 ± 2.57 9.64 ± 2.43 0.000
APACHE II Score 8.34 ± 5.84 16.3 ± 7.35a 0.000
48 h after admission
BUN (mmol/L) 5.52 ± 1.45 11.4 ± 2.99 0.000
Scr (μmol/L) 57.4 ± 15.0 178.4 ± 58.8 0.000
U KIM-1 (ng/mL) 4.62 ± 1.25 6.18 ± 1.62 0.001
UIL-18 (pg/mL) 5.80 ± 2.16 10.9 ± 2.86 0.000
Mechanical ventilation,n (%) 0 5(45.5) /
CRRT,n (%) 0 5(45.5) /
APACHE II Score 8.36 ± 6.38 29.3 ± 7.77a 0.000
Wihtin 4 weeks
Mortality,n (%) 0 4(36.4) /
APACHE II, Acute Physiology and Chronic Health Evaluation II; BUN, blood urea nitrogen; CRRT, continuous renal replacement therapy; IL-18, interleukin-18; KIM-1,
kidney injury molecule-1; Scr, serum creatinine; TBSA, total burn surface area
aAKI group vs. non-AKI group
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increase in Scr is delayed, it is not a reliable early bio-
marker for AKI. Therefore, sensitive, specific, and reliable
biomarkers are urgently needed. Increases in the expres-
sion of urinary KIM-1 and IL-18 and other biological
markers have recently been reported to occur within 2 h
of renal injury and gradually approach their peaks [9, 19].
The aim of our study was therefore to choose the markers
of acute renal tubular damage to diagnose AKI. Because
some studies have shown that use of single biomarkers
may not be adequate to determine whether AKI is due to
kidney heterogeneity or various dysfunctions, we com-
bined KIM-1 with IL-18 and clinical observations for early
diagnosis of AKI in burn patients and rapid therapeutic
interventions.
Urinary KIM-1 may be one of the most stable, reliable,
sensitive, and specific indicators for early diagnosis of AKI.
KIM-1, a type I transmembrane protein, was identified in
1998 by Lim et al in a study of ischemia-reperfusion in rat
kidney cells using representational difference analysis [20,
21]. Han et al [22] were the first to detect the significant ex-
pression of KIM-1 in humans using renal biopsy specimens
of patients with acute tubular necrosis. Their study revealed
that urinary KIM-1 showed a progressive increase within
12 h following early acute renal ischemia. Other recent
studies have shown that the detection of KIM-1 in kidney
tissue and urine facilitates the early diagnosis of AKI and is
a better indictor than Scr or serum BUN [12, 23, 24]. Our
study also revealed that urinary KIM-1 levels were
significantly higher in patients with severe burns than in
the healthy control group and showed a significantly
increasing trend with worsening burn severity. Urinary
KIM-1 levels were also significantly higher in the moderate-
and severe-burn-group patients with AKI than in those
without AKI and were detected earlier than elevated Scr.
Moreover, correlation analysis indicated that urinary KIM-1
levels were correlated with Scr, suggesting that urinary
KIM-1 can be used as an early indicator of AKI.
IL-18 is a proinflammatory factor that promotes en-
dogenous inflammatory processes. Patients with AKI as a
complication of preeclampsia, contrast-induced nephropa-
thy, and coronary angiography have significant increases
in urinary IL-18 prior to the occurrence of increases in
Scr and serum BUN [12, 13, 18]. In non-septic patients,
urinary IL-18 was significantly elevated 2 days prior to the
increase in Scr [12]. According to Risk, Injury, Failure,
Loss of kidney function, and End-stage kidney disease
(RIFLE) criteria, urinary IL-18 levels of AKI patients
increased significantly 24–48 h prior to the occurrence
of AKI, and urinary IL-18 levels were associated with
the severity of AKI, thus suggesting that IL-18 is an
important indicator for the prediction of AKI and sub-
sequent mortality [25]. In fact, the sensitivity and spe-
cificity of urinary IL-18 levels for the diagnosis of AKI
are greater than 90 % [6, 26]. In the present study, we
also found that the urinary IL-18 levels of all three
groups of burn patients were similar to those of the
Fig. 2 Dynamic changes in urinary KIM-1 and IL-18 levels between AKI and non-AKI groups on admission and 48 h post admission. ## Significant
difference (p < 0.01) between groups. AKI, acute kidney injury; BUN, blood urea nitrogen; KIM-1, kidney injury molecule-1
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Fig. 3 Relationships between urinary KIM-1 levels and a serum BUN, b Scr, c APACHE II Score, d TBSA, and e TDBA; and between urinary IL-18
levels and f serum BUN, g Scr, and h TDBA. APACHE II, Acute Physiology and Chronic Health Evaluation II; BUN, blood urea nitrogen; KIM-1, kidney
injury molecule-1; Scr, serum creatinine; TDBA, third-degree burn area; TBSA, total burn surface area
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Fig. 4 ROC curves showing probability of urinary KIM-1 and urinary IL-18 to predict acute kidney injury on admission. AUC, area under the ROC curve;
KIM-1, kidney injury molecule-1; IL-18, interleukin-18; ROC, receiver operating characteristic
Fig. 5 ROC curve showing the probability of the combination of urinary KIM-1 and urinary IL-18 to predict acute kidney injury on admission. The AUC for
the combination was 0.904. AUC, area under the ROC curve; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; ROC, receiver operating characteristic
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control group. However, urinary IL-18 levels were signifi-
cantly higher in the AKI group than in non-AKI group, were
detected earlier than increases in Scr, and were significantly
correlatedwith Scr and serumBUN, thereby also suggesting
that urinary IL-18 is a useful biomarker for predicting early
AKIinburn-injurypatients.
In the present study, ROC curve analysis of the ability
of KIM-1 and IL-18 to predict AKI on admission dem-
onstrated both KIM-1 and IL-18 to have high sensitivity
and specificity, with AUCs of 0.846 and 0.819, respectively.
However, the ability of the combination of urinary KIM-1
with IL-18 to predict AKI yielded an AUC of 0.904.
The results of our NRI and IDI analyses to estimate
the predictive power of each biomarker also indicated
that urinary KIM-1 combined with IL-18 may be a sensi-
tive biomarker to predict early AKI.
Finally, we found urinary KIM-1 to have a significant
positive correlation with the TBSA, TDBA, the pres-
ence of rhabdomyolysis, and APACHE II score, again
suggesting that urinary KIM-1 may be associated with
disease severity in burn patients, but this will require
further investigation. Our results, which also suggest
that urinary KIM-1 and IL-18 levels in the post-burn
period may predict AKI, are consistent with recent re-
ports demonstrating NGAL as an indicator of AKI in
burn patients [10, 11].
There are some limitations to our study. We did not
collect 6-, 12-, 24-, and 36-h urine and blood specimens
in the post-burn period to observe the dynamic changes
in these indicators; further research will be necessary to
clarify these.
Conclusions
Our results suggest that urinary KIM-1 and IL-18 may
be used as early, sensitive indicators of AKI in patients
with varying degrees of burns and may provide clinical
clues that can be used for early prevention of AKI.
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